News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Bayer Corporation Accelerates Development of Key Drug Xarelto
September 2, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MUNICH, Aug 31 (Reuters) - Bayer AG is to accelerate the development programme for Xarelto, an anticoagulant that is its most important pipeline product, the German drugmaker said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
Cancer
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
October 28, 2026
·
2 min read
·
Nick Paul Taylor
